AzTrials
AzTrials

Congenital Central Hypoventilation SyndromeNCT03088020

International Congenital Central Hypoventilation Syndrome (CCHS) Registry and CCHS SHARE

An observational study of Congenital Central Hypoventilation Syndrome, run by Ilya Khaytin at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The Center for Autonomic Medicine in Pediatrics (CAMP), in collaboration with leading CCHS clinicians, scientists, and patient advocacy groups around the world has built the first International CCHS (Congenital Central Hypoventilation Syndrome REDCap (Research Electronic Data Capture) Registry. Read more about this study

Who is it for?
Any age
How many people
1,000 participants
Where
1 siteUnited States
Study dates
24 Jun 2013to 31 Dec 2032
How long will I take part?
20 Years
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: CCHS patients with confirmed PHOX2B mutations

Who may be able to join

  • Individuals with PHOX2B mutation-confirmed CCHS.

Who cannot join

  • Individuals without PHOX2B mutation-confirmed CCHS.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

United States1 site, 1 recruiting
  • Ann & Robert H. Lurie Children's Hospital of Chicago and the Stanley Manne Children's Research Institute

    Chicago, Illinois, 60611

    Erin S Lonergan, BS, 312-227-3300, CAMP@luriechildrens.org

    Recruiting

Other trials in United States

About this study

Official title: International Congenital Central Hypoventilation Syndrome (CCHS) REDCap Registry and CCHS Secure Health-hub Advancing Research Efforts

The Center for Autonomic Medicine in Pediatrics (CAMP), in collaboration with leading CCHS clinicians, scientists, and patient advocacy groups around the world has built the first International CCHS (Congenital Central Hypoventilation Syndrome REDCap (Research Electronic Data Capture) Registry. This registry is an international collaboration to capture CCHS natural history data with CCHS patients and their physicians recruited from around the world. This registry is part of a CCHS natural history study that includes the CCHS Secure Health-hub Advancing Research Efforts (CCHS-SHARE), a natural history data platform shared with the broader CCHS research and patient community to house extensive longitudinal, de-identified data. Inclusion of registry data in CCHS-SHARE is optional.

The purpose of this IRB-approved research study is to gain a better understanding of the natural history of CCHS, including the various clinical manifestations of CCHS with advancing age, and as related to each patient's specific PHOX2B mutation. With a better understanding of CCHS natural history, we will be able to better anticipate healthcare needs and to provide more accurate guidelines to healthcare providers world-wide in caring for patients with CCHS.

The study aims to obtain detailed phenotypic information (information about health and well-being) on patients with CCHS and their families. Participation would require filling out a confidential survey that asks questions regarding phenotype and past medical history. Involvement in the project is completely voluntary and there is no compensation for taking part. However, this project will help us learn more about this disease, with the goal of advancing treatment.

Read the detailed description

CCHS is a disorder characterized by alveolar hypoventilation with a control of breathing deficit, and symptoms of autonomic nervous system (ANS) dysregulation (ANSD). This study aims to develop a patient registry for CCHS, which will provide crucial insight into disease development, improving outcome in these children through improving early recognition of the disorder, understanding the phenotypic spectrum, and evolution of CCHS natural history. Data will be stored in REDCap (Research Electronic Data Capture) system a secure web application designed exclusively to support data capture for research studies in a secure manner. The REDCap server is hosted securely at Northwestern University, behind a firewall, with virus protection, and using Secure Socket Layer (SSL) authentication to encrypt communication between a user and the server. Protected Health Information (PHI) will be labeled as such in the database and access to it will be restricted to the Principal Investigator (PI) and key personnel participating in the consent process and follow up contact of participants.

Participants in the International CCHS REDCap Registry will be identified and recruited from CAMP's registry of new, current, and past CCHS referrals, including CCHS patients referred for PHOX2B testing and/or consultation. Additionally, patients may also be recruited via the internet using emails, Facebook pages, and mailing lists for family groups. Anyone interested will be offered inclusion into the International CCHS Registry. Participants will be able to participate remotely, from their homes or locations where they have internet, phone, and computer access.

Data collected through the REDCap registry will be de-identified and analyzed. Patients enrolled in this study will be offered participation in CCHS-SHARE and the NIH Global Rare Disease Registry (GRDR). These are both optional parts of the study, and are not required for inclusion. The CCHS-SHARE is a data repository that houses de-identified clinical and registry data on CCHS patients, empowering data sharing across the CCHS research community. The GRDR is established by the NIH Office of Rare Disease Research. The goal of the GRDR is to establish a data repository of de-identified patient data, aggregated in a standardized manner, using Common Data Elements (CDEs) and standardized terminology. De-identification of patient's data will utilize the Global Unique Identifiers (GUID) system. Lurie Children's Hospital will retain ownership of all data shared with CCHS-SHARE and the GRDR. The de-identified data in CCHS-SHARE and GRDR will be available to all investigators to enable analyses across many rare diseases and to facilitate various biomedical studies, including clinical trials, in pursuit of developing drugs and therapeutics to improve the healthcare and the quality of life for the many millions of people who are diagnosed with rare diseases.

Any patient agreeing to be part of CCHS-SHARE and/or GRDR will have their data de-identified and this de-identified data exported and shared with CCHS-SHARE and the GRDR. These participants are also given the option to be contacted for participation in clinical trials. If this option is chosen, any researcher accessing de-identified information through CCHS-SHARE and GRDR and planning to conduct a clinical trial will be allowed to contact the CAMP project coordinator to ask that patients fitting the profile of needed participants be contacted and offered inclusion. No de-identified information will be shared with researchers outside of CAMP, rather the CAMP project coordinator will contact identified patients fitting participation criteria to share contact information and details for the clinical trial. Interested patients will then be given to the option to contact researchers conducting clinical trials at their discretion.

Keywords
CCHS, PHOX2B, Paired-like Homeobox gene PHOX2B, autonomic nervous system dysregulation, control of breathing, Hirschsprung disease, neural crest tumors, neuroblastoma, ganglioneuroma, ganglioneuroblastoma, artificial ventilation, diaphragm pacing
Medical subject headings
Congenital central hypoventilation syndrome, Hirschsprung Disease, Neuroblastoma, Ganglioneuroma, Ganglioneuroblastoma

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Longitudinal phenotype in CCHS

    Collection of longitudinal disease history in 400 CCHS patients

    Measured: 20 years

Secondary outcomes (2)
  1. Sensitive markers of disease progression by PHOX2B mutation/genotype

    Evaluate patient reported outcome measures to determine sensitive markers of disease progression for use in intervention trials

    Measured: 20 years

  2. Integration of CCHS Registry and Global Rare Diseases Patient Registry (GRDR)

    Develop a patient registry for CCHS for use with the CCHS Secure Health-hub Advancing Research Efforts" (CCHS-SHARE) and the global rare diseases patient registry and data repository (GRDR)

    Measured: 20 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Mar 2017
  2. Study start24 Jun 2013
  3. Primary completion31 Dec 2031 (estimated)
  4. Study completion31 Dec 2032 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
1,000 participants (estimated)
Target duration
20 Years
IDs, dates and publications
ClinicalTrials.gov ID
NCT03088020
Sponsor's protocol ID
2013-15230
Status last verified
Aug 2026
First submitted
17 Mar 2017
Last updated
3 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Congenital Central Hypoventilation Syndrome, run by Ilya Khaytin at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 3 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Casey Rand, BS (312-227-3300, Crand@luriechildrens.org), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Longitudinal phenotype in CCHS (time frame: 20 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Sep 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in